Literature DB >> 20585817

Primary progressive multiple sclerosis and generalized myasthenia gravis: an uncommon association.

G Bigliardi1, J Mandrioli, F Valzania, P Nichelli, N Casula, A M Simone, P Sola.   

Abstract

The co-occurrence of myasthenia gravis (MG) and multiple sclerosis (MS) is rare, and in all the described cases MS had a relapsing-remitting course and the diseases had a benign clinical evolution. We describe herewith a patient with primary progressive MS (PPMS) and generalized MG with severe clinical course. This is the first report on a case of PPMS associated to MG. Studies on the histology and pathogenesis show that neurodegeneration is predominant over inflammation in PPMS, even if cellular and humoral immune-mediated mechanisms are thought to maintain a crucial importance in the development and progression of this form of disease. In the present case, the detection of cerebrospinal fluid IgM oligoclonal bands support the hypothesis of a possible role of antibody-mediated immunity in PPMS and suggest that humoral immunity may take part in the concomitant development of both MS and MG.

Entities:  

Mesh:

Year:  2010        PMID: 20585817     DOI: 10.1007/s10072-010-0358-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  21 in total

1.  Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS.

Authors:  L M Villar; J Masjuan; P González-Porqué; J Plaza; M C Sádaba; E Roldán; A Bootello; J C Alvarez-Cermeño
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

2.  Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.

Authors:  J Dionisiotis; Y Zoukos; T Thomaides
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

3.  Occurrence of CNS demyelinating disease in patients with myasthenia gravis.

Authors:  I Kister; J Herbert; M L Swerdlow; R Bergamaschi; G Piccolo; J Oger
Journal:  Neurology       Date:  2007-04-17       Impact factor: 9.910

4.  Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.

Authors:  G Blake; S Murphy
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

5.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

6.  Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

Authors:  Luisa M Villar; María C Sádaba; Ernesto Roldán; Jaime Masjuan; Pedro González-Porqué; Noelia Villarrubia; Mercedes Espiño; José A García-Trujillo; Alfredo Bootello; José C Alvarez-Cermeño
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

7.  Cortical demyelination and diffuse white matter injury in multiple sclerosis.

Authors:  Alexandra Kutzelnigg; Claudia F Lucchinetti; Christine Stadelmann; Wolfgang Brück; Helmut Rauschka; Markus Bergmann; Manfred Schmidbauer; Joseph E Parisi; Hans Lassmann
Journal:  Brain       Date:  2005-10-17       Impact factor: 13.501

8.  Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia.

Authors:  C M Isbister; P J Mackenzie; D Anderson; N K Wade; J Oger
Journal:  Mult Scler       Date:  2003-12       Impact factor: 6.312

9.  Myasthenia gravis associated with multiple sclerosis. Epidemiological survey and immunological findings.

Authors:  H Somer; K Müller; E Kinnunen
Journal:  J Neurol Sci       Date:  1989-01       Impact factor: 3.181

10.  Influence of oligoclonal IgM specificity in multiple sclerosis disease course.

Authors:  Lm Villar; N García-Barragán; M Espiño; E Roldán; Mc Sádaba; J Gómez-Rial; P González-Porqué; Jc Alvarez-Cermeño
Journal:  Mult Scler       Date:  2007-10-17       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.